Press Release: Second Genome : Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

BRISBANE, Calif., Feb. 10, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today announced that the Company will advance SG-5-00455, which targets plasminogen activator...